Achmad Nabil Hafidh Maftuhin, . (2022) PROFIL EFEKTIVITAS DAN KEAMANAN REMDESIVIR DALAM PENATALAKSANAAN PASIEN COVID-19: SYSTEMATIC REVIEW. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.
![[img]](http://repository.upnvj.ac.id/style/images/fileicons/text.png) |
Text
ABSTRAK.pdf Download (34kB) |
|
Text
AWAL.pdf Download (888kB) |
|
Text
BAB 1.pdf Download (97kB) |
|
Text
BAB 2.pdf Restricted to Repository UPNVJ Only Download (741kB) |
|
Text
BAB 3.pdf Restricted to Repository UPNVJ Only Download (207kB) |
|
Text
BAB 4.pdf Restricted to Repository UPNVJ Only Download (482kB) |
|
Text
BAB 5.pdf Download (30kB) |
|
Text
DAFTAR PUSTAKA.pdf Download (168kB) |
|
Text
RIWAYAT HIDUP.pdf Restricted to Repository UPNVJ Only Download (87kB) |
|
Text
LAMPIRAN.pdf Restricted to Repository UPNVJ Only Download (368kB) |
|
Text
HASIL PLAGIARISME.pdf Restricted to Repository staff only Download (335kB) |
|
Text
ARTIKEL KI.pdf Restricted to Repository staff only Download (856kB) |
Abstract
Coronavirus disease 2019 (COVID-19) has become a global pandemic since March 2020. Many of the medical staff are still doubtful about the efficacy and safety of the antivirals in the management of COVID-19. Remdesivir was obtained emergency clearance (EUA) from the FDA. we carried out a systematic research review to evaluate safety profile and the efficacy of remdesivir. From the results of the study time to recovery had a significant difference RR 1.29 (95% CI 1.12-149[P<0.0001]), time to improvement was not significant HR 0.94 (95% CI 0.80-1 ,10[P=0.44]), patients discharged did not differ significantly between the remdesivir and placebo groups (RR: 1.27 (95% CI 1.10-1.49), The duration of hospitalization, a shorter duration of stay in the remdesivir group (median 12 days vs. 17 days), mortality was not significantly different, oxygen demand was significantly different in users of supplemental oxygen supplementation HR 0.850 (95% CI 0.798000.906[P<0.001]). For the Safety, there was no significant difference. the optimal time to recovery and the level of safety is still acceptable. It can be said that the efficacy of administering remdesivir is still not sufficient to provide the best service to COVID-19 patients and its safety is still acceptable.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Additional Information: | [No.Panggil: 1710211133] [Pembimbing: Ryan Herardi] [Penguji: Yudhi Nugraha] |
| Uncontrolled Keywords: | COVID-19, remdesivir, efectiveness, Safety |
| Subjects: | R Medicine > RC Internal medicine |
| Divisions: | Fakultas Kedokteran > Program Studi Kedokteran (S1) |
| Depositing User: | Achmad Nabil Hafidh Maftuhin |
| Date Deposited: | 06 Sep 2022 04:01 |
| Last Modified: | 06 Sep 2022 04:01 |
| URI: | http://repository.upnvj.ac.id/id/eprint/19966 |
Actions (login required)
 |
View Item |